This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Manny Villafaña Announces The Strengthening Of The Kips Bay Medical Management Team

Manny Villafaña, Chairman and Chief Executive Officer of Kips Bay Medical, Inc. (NASDAQ: KIPS) announced the addition of two new officers to the Company’s management team and the departure of one officer.

On May 2, 2011, Mr. Michael Reinhardt will join the Company as its Vice President of Sales & Marketing. Mr. Reinhardt has thirty years of sales and marketing experience. Mr. Reinhardt’s recent experience includes serving as Vice President of Global Marketing of ATS Medical, Inc., a provider of heart valves and life-saving cardiac surgery products and Vice President of Global Marketing for the Cardiac Surgery Division of St Jude Medical, Inc. Mr. Reinhardt holds a Master of Business Administration in general business from Baruch College, New York, NY and a Bachelor of Business Administration in Marketing from Ohio University, Athens, OH.

On May 16, 2011, Mr. Randall K. LaBounty will join the Company as its Vice President of Regulatory and Clinical Affairs. Mr. LaBounty has over twenty years of experience working in medical research with sixteen years of experience in cardiovascular medical devices. Prior to joining the Company, Mr. LaBounty served as Vice President of Clinical Research of Osprey Medical and as the Vice President of Clinical and Regulatory Affairs for Lumen Biomedical, Inc. Mr. LaBounty holds a Master of Science in Biostatistics and a Bachelor of Science in Genetics and Cell Biology from the University of Minnesota.

Michael P. Winegar, Vice President of Regulatory Affairs, Chief Operating Officer, and Director of Kips Bay Medical, Inc. (the “Company”), recently notified the Company of his intention to retire from his position as an executive officer and employee of the Company. Mr. Winegar will remain with the Company in his current position for a period of time to participate in the transition and training of the Company’s new Vice President of Regulatory and Clinical Affairs and has agreed to provide assistance to the Company and our Board of Directors on a consulting basis after his final separation from employment. Mr. Villafaña will assume responsibility for oversight of the operations of the Company upon Mr. Winegar’s departure. Mr. Winegar will not be nominated for re-election as a Director at the Company’s 2011 Annual Meeting of Stockholders, and will remain as a Director of the Company until such meeting.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,856.78 -278.94 -1.54%
S&P 500 2,071.26 -29.78 -1.42%
NASDAQ 4,927.37 -55.4390 -1.11%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs